mk 0663 has been researched along with celecoxib in 73 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (celecoxib) | Trials (celecoxib) | Recent Studies (post-2010) (celecoxib) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 5,273 | 843 | 2,428 |
| Protein | Taxonomy | mk 0663 (IC50) | celecoxib (IC50) |
|---|---|---|---|
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | 0.021 | |
| Prostaglandin E synthase | Homo sapiens (human) | 0.4825 | |
| Histone deacetylase 3 | Homo sapiens (human) | 1.637 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 7.9667 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.057 | |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | 6.5 | |
| Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | 0.0881 | |
| Catechol O-methyltransferase | Mus musculus (house mouse) | 0.036 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.371 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.1555 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.0925 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 5.271 | |
| Procathepsin L | Homo sapiens (human) | 0.56 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 7.308 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.07 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.295 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.002 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.516 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.12 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 3.6401 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3.5499 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 7.308 | |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.006 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 6.276 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3818 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.4028 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 7.6 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.637 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.03 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.6343 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 7.7 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.431 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.045 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1.411 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.81 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.016 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.05 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.3 | |
| Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | 5.57 | |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | 0.9 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1.637 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.637 | |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.04 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1.14 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1.637 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 35 (47.95) | 29.6817 |
| 2010's | 28 (38.36) | 24.3611 |
| 2020's | 10 (13.70) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, Y; Choi, JK; Choi, YH; Chung, S; Jeong, YS; Kim, JK; Kim, JY; Koh, HJ; Lee, KW; Lim, KM; Moh, JH; Noh, MS; Oh, YI; Park, YH; Shin, SS | 1 |
| Beswick, P; Bingham, S; Bountra, C; Brown, T; Browning, K; Campbell, I; Chessell, I; Clayton, N; Collins, S; Corfield, J; Guntrip, S; Haslam, C; Lambeth, P; Lucas, F; Mathews, N; Murkit, G; Naylor, A; Pegg, N; Pickup, E; Player, H; Price, H; Stevens, A; Stratton, S; Wiseman, J | 1 |
| Augustyniak, ME; Earl, RA; Garvey, DS; Janero, DR; Khanapure, SP; Letts, LG; Martino, AM; Murty, MG; Schwalb, DJ; Shumway, MJ; Trocha, AM; Young, DV; Zemtseva, IS | 1 |
| Barreiro, EJ; Fraga, CA; Lima, LM; Sant'Anna, CM; Sperandio da Silva, GM | 1 |
| Beswick, PJ; Bingham, S; Bountra, C; Carter, MC; Chambers, LJ; Chessell, IP; Clayton, NM; Collins, SD; Corfield, JA; Gleave, RJ; Green, RH; Hartley, CD; Kleanthous, S; Lambeth, PF; Lucas, FS; Mathews, N; Naylor, A; Page, LW; Payne, JJ; Pegg, NA; Price, HS; Skidmore, J; Stevens, AJ; Stocker, R; Stratton, SC; Stuart, AJ; Swarbrick, ME; Wiseman, JO | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ramajayam, R | 1 |
| Bachman, KE; Bonnette, WG; Chen, H; Connolly, PJ; Dallas, S; Diloreto, KA; Dong, Y; Edwards, JP; Evans, DC; Ghosh, A; King, P; Li, X; Liao, D; Pande, V; Patel, S; Pietrak, B; Sensenhauser, C; Shi, Y; Suarez, J; Szewczuk, L; Tian, G; Wang, J; Wilde, T; Zhang, Z | 1 |
| Ouellet, M; Percival, MD; Riendeau, D | 1 |
| Hardy, KJ; McMurray, RW | 1 |
| Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT | 1 |
| Chan, VS | 1 |
| Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B | 1 |
| Hochberg, MC | 1 |
| Meena, S; Nageswara Rao, R; Raghuram Rao, A | 1 |
| Mullangi, R; Pavan Kumar, VV; Ramani, AV; Srinivas, NR; Vinu, MC | 1 |
| Krüger, K | 1 |
| Caballero-Fonseca, F; Capriles-Hulett, A; Sánchez-Borges, M | 1 |
| Andersohn, F; Garbe, E; Schade, R; Suissa, S | 1 |
| Boshier, A; Friedmann, P; Layton, D; Marshall, V; Shakir, SA | 1 |
| Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM | 1 |
| Broich, K; Heim, HK | 1 |
| Hilário, MO; Len, CA; Terreri, MT | 1 |
| Tabrizchi, R | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Bjarnason, NH; Gøtzsche, PC | 1 |
| Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C | 1 |
| Klotz, U; Shi, S | 1 |
| Cavanaugh, PF; Chappell, DL; Dallob, AL; Flynn, ME; Hilliard, DA; Larson, PJ; Laterza, OF; Miller, J; Royalty, J; Schwartz, JI; Snyder, KM; Wagner, JA | 1 |
| Bingham, CO; Bird, SR; Smugar, SS; Tershakovec, AM; Xu, X | 1 |
| Lesaffre, E | 2 |
| Caspers, P; Gijsen, R; Jochemsen, H; van Dijk, L | 1 |
| Diza, E; Gika, HG; Michopoulos, F; Nikolaidis, P; Settas, L; Smith, C; Theodoridis, G; Theodoridou, A; Wilson, ID | 1 |
| Sharma, P; Suresh, S | 1 |
| Bingham, CO; Smugar, SS; Tershakovec, AM; Wang, H | 1 |
| Mahadik, KR; Paradkar, AR; Shimpi, SL | 1 |
| Avila, R; Cimbollek, S; Quiralte, J | 1 |
| Choy, EH; Gaugris, S; Jansen, JP; Nash, JT; Ostor, A; Stam, W | 1 |
| Elliott, WJ | 1 |
| Chang, FY; Chen, TS; Hsiang, KW; Lee, KC; Lee, SD; Lin, HC; Lin, HY; Lu, CL; Luo, JC | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| Boonriong, T; Glabglay, P; Nimmaanrat, S; Tangtrakulwanich, B | 1 |
| Pilatti, GL; Santos, FA; Steffens, JP | 1 |
| Bingham, CO; Gammaitoni, A; Peloso, PM; Smugar, SS; Wang, H | 1 |
| Janovsky, M; Krsiak, M | 1 |
| Calvello, R; Carbone, ML; Cianciulli, A; Malerba, P; Panaro, MA; Perrone, MG; Scilimati, A; Vitale, P | 1 |
| Dávila, I; González, A; Laffond, E; Moreno, E; Muñoz-Bellido, F; Ponce, V | 1 |
| Caro Gutiérrez, D; Gómez de la Fuente, E; López Estebaranz, JL; Pampín Franco, A | 1 |
| Ariano, C; Baldi, C; Cantatrione, S; Cioppa, C; De Vecchis, R; Di Biase, G; Giasi, A; Valente, L | 1 |
| Baek, HJ; Bin, SI; Cho, YJ; Cukrow, DM; Kang, SB; Kim, SS; Lee, SW; Mehta, A; Min, BW; Moon, KH; Moon, SH; Park, YW; Shim, SC; Skuban, A; Song, YW; Vandormael, K; Yan, L; Yoo, DH; Yoo, MC; Yoo, WH | 1 |
| Aujla, U; Bjarnason, I; Kvasnovsky, CL | 1 |
| Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
| Askling, J; Jacobsson, LT; Jakobsen, AK; Kristensen, LE; Nilsson, F | 1 |
| Dulski, M; Grzybowska, K; Jurkiewicz, K; Knapik, J; Paluch, M; Rams-Baron, M; Ratuszna, A; Sawicki, W; Smolka, W; Wojnarowska, Z | 1 |
| Hansen, SH; Skonberg, C; Syed, M | 1 |
| Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG | 1 |
| Katchamart, W; Suwanawiboon, B; Tantayakom, P; Teerawattananon, C | 1 |
| Ghanghas, P; Jain, S; Rana, C; Sanyal, SN | 2 |
| Carracedo-Martínez, E; Figueiras, A; Pia-Morandeira, A | 1 |
| Davydkin, IL; Zolotovskaia, IA | 1 |
| Martín Arias, LH; Martín González, A; Sanz Fadrique, R; Vazquez, ES | 1 |
| Amaro, C; Ferreira, ML; Miroux-Catarino, A; Silva, L; Viana, I | 1 |
| Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K | 1 |
| Ahn, K; Connolly, P; Suarez, J; Tian, G; Zhang, Z | 1 |
| Bahra, A; Farag, M | 1 |
| Ding, X; Li, X; Lu, N; Wang, Y; Wu, Z | 1 |
| Hjemdahl, P; Stiller, CO | 1 |
| Pedersen, L; Schmidt, M; Sørensen, HT | 1 |
| González-Fernández, T; López-Freire, S; Méndez-Brea, P; Romero-Sánchez, L | 1 |
| Cvijić, S; Dahan, A; Dukhno, O; Partook-Maccabi, M; Porat, D; Vainer, E | 1 |
| Chau, C; Cheung, G; Chu, EC; Huang, KH; Tam, D | 1 |
20 review(s) available for mk 0663 and celecoxib
| Article | Year |
|---|---|
Medicinal chemistry of vicinal diaryl scaffold: A mini review.
Topics: Carbonic Anhydrase IV; Chemistry, Pharmaceutical; Cyclooxygenase 2 Inhibitors; Drug Discovery; Humans; Hydrocarbons, Aromatic; Structure-Activity Relationship | 2019 |
Cox-2 inhibitors: today and tomorrow.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones | 2002 |
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Industry; Etodolac; Etoricoxib; Lactones; Models, Chemical; Pyrazoles; Pyridines; Spectrophotometry; Sulfonamides; Sulfones; Ultraviolet Rays | 2005 |
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etoricoxib; Gout; Humans; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Rheumatic Diseases; Spondylitis, Ankylosing; Sulfonamides; Sulfones | 2005 |
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.
Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Fever; Humans; Hypersensitivity, Immediate; Inflammation; Leukotrienes; Meloxicam; Naproxen; Pain; Prostaglandins; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Treatment Outcome | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2008 |
Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.
Topics: Aged; Analysis of Variance; Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Female; Health Status Indicators; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Treatment Outcome | 2008 |
Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; Prognosis; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Time Factors; Treatment Outcome | 2009 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Naproxen; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2014 |
Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etoricoxib; Gastrointestinal Tract; Humans; Inflammatory Bowel Diseases; Observational Studies as Topic; Pain; Pyrazoles; Pyridines; Recurrence; Sulfonamides; Sulfones | 2015 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bayes Theorem; Celecoxib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Outcome Assessment, Health Care; Proportional Hazards Models; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2016 |
Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Isoxazoles; Postoperative Hemorrhage; Pyridines; Risk Factors; Sulfones | 2017 |
Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Etoricoxib; Humans; Observational Studies as Topic; Risk Factors | 2019 |
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes | 2022 |
8 trial(s) available for mk 0663 and celecoxib
| Article | Year |
|---|---|
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Urticaria | 2005 |
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pyrazoles; Pyridines; Severity of Illness Index; Sulfonamides; Sulfones; Thrombosis; Treatment Outcome | 2007 |
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Body Weight; Celecoxib; Constipation; Creatinine; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Electrolytes; Etoricoxib; Female; Headache; Humans; Male; Middle Aged; Naproxen; Potassium; Prostaglandins; Pyrazoles; Pyridines; Sodium; Sulfonamides; Sulfones; Thromboxane B2 | 2007 |
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thromboxane B2 | 2008 |
Comparing etoricoxib and celecoxib for preemptive analgesia for acute postoperative pain in patients undergoing arthroscopic anterior cruciate ligament reconstruction: a randomized controlled trial.
Topics: Adolescent; Adult; Analgesia; Arthroscopy; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Middle Aged; Pain, Postoperative; Preoperative Care; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Young Adult | 2010 |
The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Celecoxib; Chronic Periodontitis; Cyclooxygenase 2 Inhibitors; Debridement; Dental Anxiety; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gingival Hemorrhage; Humans; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Placebos; Premedication; Prospective Studies; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Surgical Flaps; Treatment Outcome; Young Adult | 2011 |
Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis; Placebos; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Treatment Outcome | 2011 |
Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial.
Topics: Adult; Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Republic of Korea; Sulfonamides; Sulfones; Treatment Outcome | 2014 |
45 other study(ies) available for mk 0663 and celecoxib
| Article | Year |
|---|---|
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Furans; Humans; In Vitro Techniques; Isoenzymes; Macrophages, Peritoneal; Male; Membrane Proteins; Mice; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship | 2004 |
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Biological Availability; Brain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Freund's Adjuvant; Humans; Infusions, Intravenous; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridazines; Rats; Structure-Activity Relationship | 2004 |
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
Topics: Administration, Oral; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Inflammation; Male; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Sprague-Dawley; Sulfones | 2005 |
The molecular basis for coxib inhibition of p38alpha MAP kinase.
Topics: Algorithms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Databases, Factual; Enzyme Activation; Enzyme Inhibitors; p38 Mitogen-Activated Protein Kinases; Prostaglandin-Endoperoxide Synthases; Protein Binding; Quantitative Structure-Activity Relationship | 2005 |
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Ethers; Humans; Inflammation; Inhibitory Concentration 50; Mice; Molecular Structure; Neurodegenerative Diseases; Pyrimidines; Rats; Sulfones | 2009 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoricoxib; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Structure-Activity Relationship | 2021 |
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones | 2001 |
Pharmacological characterisation of a rat model of incisional pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Evaluation, Preclinical; Etoricoxib; Foot; Gabapentin; gamma-Aminobutyric Acid; Hindlimb; Hyperalgesia; Indomethacin; Male; Morphine; Muscle, Skeletal; Naproxen; Nociceptors; Pain Threshold; Pain, Postoperative; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sulfonamides; Sulfones; Time Factors; Weight-Bearing | 2004 |
Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection.
Topics: Animals; Celecoxib; Chromatography, High Pressure Liquid; Etoricoxib; Humans; Isoxazoles; Ketoprofen; Male; Pyrazoles; Pyridines; Rats; Rats, Wistar; Reproducibility of Results; Salicylic Acid; Spectrophotometry, Ultraviolet; Sulfonamides; Sulfones | 2006 |
Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dose-Response Relationship, Drug; Etoricoxib; Female; Humans; Lactones; Logistic Models; Male; Medical Records Systems, Computerized; Middle Aged; Odds Ratio; Pyrazoles; Pyridines; Sulfonamides; Sulfones; United Kingdom | 2006 |
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; England; Etoricoxib; Female; Humans; Incidence; Lactones; Male; Middle Aged; Pyrazoles; Pyridines; Research Design; Retrospective Studies; Skin; Stevens-Johnson Syndrome; Sulfonamides; Sulfones; Surveys and Questionnaires | 2006 |
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Approval; Drug Evaluation, Preclinical; Etoricoxib; European Union; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboembolism | 2006 |
Coxibs: can this class of drugs survive?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2005 |
COX-2 inhibitor.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Osteoarthritis; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones | 2007 |
Use and misuse of the p-value.
Topics: Biomedical Research; Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Sample Size; Statistics as Topic; Sulfonamides; Sulfones | 2008 |
Superiority, equivalence, and non-inferiority trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Myocardial Infarction; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Statistics as Topic; Sulfonamides; Sulfones; Thrombolytic Therapy; Treatment Outcome | 2008 |
Frequency of ill-founded off-label prescribing in Dutch general practice.
Topics: Adolescent; Adult; Betahistine; Celecoxib; Child; Databases, Factual; Drug Labeling; Etoricoxib; Family Practice; Female; Humans; Male; Medication Errors; Netherlands; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Young Adult | 2009 |
Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry.
Topics: Adult; Aged; Arthritis; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Mass Spectrometry; Middle Aged; Pyrazoles; Pyridines; Reference Standards; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Sulfones; Synovial Fluid; Young Adult | 2009 |
Influence of COX-2-induced PGE2 on the initiation and progression of tail regeneration in Northern House Gecko, Hemidactylus flaviviridis.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Etoricoxib; Female; Lizards; Male; Pyrazoles; Pyridines; Regeneration; Sulfonamides; Sulfones; Tail | 2008 |
Study on mechanism for amorphous drug stabilization using gelucire 50/13.
Topics: Calorimetry, Differential Scanning; Celecoxib; Cyclooxygenase Inhibitors; Drug Compounding; Drug Stability; Etoricoxib; Excipients; Fats; Hydrogen Bonding; Oils; Povidone; Pyrazoles; Pyridines; Spectrophotometry, Infrared; Sulfonamides; Sulfones; X-Ray Diffraction | 2009 |
COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Drug Hypersensitivity; Etoricoxib; Female; Humans; Male; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2009 |
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Humans; Markov Chains; Meta-Analysis as Topic; Models, Economic; Naproxen; Pyrazoles; Pyridines; Quality-Adjusted Life Years; Severity of Illness Index; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Treatment Outcome; United Kingdom | 2010 |
Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Incidence; Logistic Models; Male; Middle Aged; Multivariate Analysis; Peptic Ulcer; Prospective Studies; Pyrazoles; Pyridines; Risk Factors; Sulfonamides; Sulfones; Taiwan | 2010 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Codeine did not increase analgesic efficacy of coxibs in contrast to that of paracetamol or ibuprofen: isobolographic analysis in mice.
Topics: Acetaminophen; Acetic Acid; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Celecoxib; Codeine; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Etoricoxib; Ibuprofen; Male; Mice; Mice, Inbred Strains; Models, Animal; Pain; Pyrazoles; Pyridines; Regression Analysis; Sulfonamides; Sulfones | 2011 |
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Topics: Animals; Aspirin; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Etoricoxib; I-kappa B Proteins; Inflammation Mediators; Intramolecular Oxidoreductases; Lipopolysaccharides; Membrane Proteins; Mice; Microglia; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Prostaglandin-E Synthases; Pyrazoles; Pyridines; RNA, Messenger; Sulfonamides; Sulfones | 2012 |
Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
Topics: Aged; Arm; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Etoricoxib; Female; Humans; Isoxazoles; Leg Dermatoses; Low Back Pain; Patch Tests; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2012 |
Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Etoricoxib; Female; Humans; Patch Tests; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2014 |
Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Registries; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Sweden; Young Adult | 2015 |
Toward a Better Understanding of the Physical Stability of Amorphous Anti-Inflammatory Agents: The Roles of Molecular Mobility and Molecular Interaction Patterns.
Topics: Anti-Inflammatory Agents; Celecoxib; Crystallization; Dielectric Spectroscopy; Drug Stability; Etoricoxib; Lactones; Pyridines; Sulfones | 2015 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |
Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Neovascularization, Pathologic; Pyridines; Rats; Rats, Sprague-Dawley; Sulfones | 2016 |
Trends in celecoxib and etoricoxib prescribing following removal of prior authorization requirement in Spain.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Utilization; Etoricoxib; Humans; Pyridines; Spain; Sulfones | 2017 |
Role of GSK-3β in Regulation of Canonical Wnt/β-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Transformation, Neoplastic; Colon; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Female; Glycogen Synthase Kinase 3 beta; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Rats, Sprague-Dawley; Sulfones; Time Factors; Wnt Signaling Pathway | 2017 |
[Cognitive-cytokine effect of nonsteroidal antiinflammatory drugs in the therapy of elderly patients with osteoarthritis].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Cognition Disorders; Cytokines; Etoricoxib; Female; Humans; Interleukin-1beta; Interleukin-6; Male; Meloxicam; Osteoarthritis; Prospective Studies; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Transforming Growth Factor beta1 | 2017 |
Bullous fixed drug eruption induced by etoricoxib, confirmed by patch testing, with tolerance to celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Blister; Celecoxib; Drug Eruptions; Etoricoxib; Female; Humans; Middle Aged; Patch Tests | 2019 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2021 |
Potent Phenylpyridine and Oxodihydrofuran Inhibitors of Cyclooxygenase-2: Optimization toward a Long Residence Time with Balanced Internal Energetics.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Discovery; Enzyme Assays; Etoricoxib; Fluorescence; Furans; Humans; Hydrogen; Kinetics; Mass Spectrometry; Models, Theoretical; Oxygen; Pyrazoles; Pyridines; Thermodynamics; Time Factors | 2021 |
Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Etoricoxib; Headache; Headache Disorders; Humans; Indomethacin | 2022 |
Association between tramadol use and risk of pneumonia in the middle-aged and elderly populations: a propensity-score matched cohort study.
Topics: Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Codeine; Cohort Studies; Diclofenac; Etoricoxib; Humans; Middle Aged; Naproxen; Pneumonia; Tramadol | 2022 |
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etodolac; Etoricoxib; Female; Heart Disease Risk Factors; Humans; Meloxicam; Risk Factors | 2022 |
[Selective cyclooxygenase-2 inhibitor hypersensitivity].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Hypersensitivity; Etoricoxib; Humans; Hypersensitivity; Male; Sulfonamides; Sulfones | 2023 |
Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics.
Topics: Bariatric Surgery; Bariatrics; Celecoxib; Cyclooxygenase 2 Inhibitors; Etodolac; Etoricoxib; Humans; Solubility | 2023 |
Remission of Dowager's hump by manipulative correction of spinal alignment: a case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Etoricoxib; Female; Headache; Humans; Kyphosis; Lordosis; Manipulation, Chiropractic; Neck Pain; Radiography; Remission Induction | 2023 |